LeMaitre Vascular (NASDAQ:LMAT) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

LeMaitre Vascular (NASDAQ:LMAT) announced its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.02, FiscalAI reports. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The company had revenue of $66.55 million during the quarter, compared to analyst estimates of $66.67 million. During the same quarter in the previous year, the business earned $0.48 EPS. The firm’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular updated its FY 2026 guidance to 2.930-3.080 EPS and its Q2 2026 guidance to 0.790-0.840 EPS.

Here are the key takeaways from LeMaitre Vascular’s conference call:

• Strong Q1 and raised full‑year outlook: Q1 delivered 11% sales growth, a 72.7% gross margin and 42% EPS growth, and the company affirmed $280M full‑year revenue guidance (≈12% organic growth) while increasing margin and EPS targets.
• Artegraft is a major growth engine: Artegraft sales rose 36% in Q1 and is now the largest product—plans include international filings (Health Canada approval; launches H2‑2026; Korea/Brazil/Vietnam/India targeted in 2027), filing for longer graft packaging in H2‑2026 (first longer‑graft sales possible H2‑2027), and an FDA pre‑submission for a Quick‑Stick AV access claim.
• Operational and financial strength: Gross‑margin expansion was driven by pricing, favorable mix (higher‑margin Artegraft) and manufacturing efficiencies; cash from operations was $15M, cash/securities were $367M, and the company continues dividends and targeted commercial investment.
• RestoreFlow and regulatory timing are mixed: RestoreFlow grew 25% in Q1 with Germany distribution starting Q2 and Ireland approval expected H2 pending audit; multiple EU and Australia filings are planned but some European implants and warehousing validations have delayed near‑term ramp, leaving timing risk.

LeMaitre Vascular Trading Down 4.8%

Shares of NASDAQ LMAT traded down $5.42 during trading on Wednesday, hitting $106.59. 106,207 shares of the company were exchanged, compared to its average volume of 202,814. The company has a debt-to-equity ratio of 0.43, a quick ratio of 10.95 and a current ratio of 12.89. The firm has a market capitalization of $2.44 billion, a PE ratio of 42.46, a P/E/G ratio of 3.21 and a beta of 0.60. The company has a fifty day moving average price of $109.28 and a 200-day moving average price of $94.17. LeMaitre Vascular has a 12-month low of $78.35 and a 12-month high of $118.01.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Thursday, May 21st will be issued a $0.25 dividend. The ex-dividend date is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 39.84%.

Key Headlines Impacting LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q1 EPS topped expectations: $0.68 vs. consensus $0.66, up from $0.48 a year ago — supports earnings momentum. LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
• Positive Sentiment: Management raised guidance: Q2 EPS guided to $0.790–$0.840 (above consensus ~$0.760) and FY26 EPS to $2.930–$3.080 (vs. consensus ~2.90) — indicates confidence in continuing earnings growth. LeMaitre Q1 2026 Financial Results (press release / guidance)
• Positive Sentiment: Board declared a quarterly cash dividend of $0.25/share (ex-dividend May 21) — modest income support, though yield (~0.9%) is small. LeMaitre Q1 2026 Financial Results
• Neutral Sentiment: Revenue grew 11.1% year-over-year, showing solid top-line growth, but was essentially in line with expectations ($66.55M vs. $66.67M consensus). LeMaitre (NASDAQ:LMAT) Posts Q1 CY2026 Sales In Line With Estimates
• Neutral Sentiment: Full earnings release and conference call materials available for deeper review (transcript posted). Useful for investors wanting color on procedure volumes, margin drivers, and buyback/dividend plans. LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue slightly missed consensus by a small margin (about $0.12M), and the sales figure was effectively “in line” not a clear beat — reduces upside surprise potential. LeMaitre Q1 earnings report (MarketBeat)

Insider Activity

In other news, CEO George W. Lemaitre sold 55,930 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares in the company, valued at $159,181,465. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Trent G. Kamke sold 1,044 shares of the company’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider owned 6,677 shares of the company’s stock, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 215,438 shares of company stock valued at $23,062,911. 7.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC purchased a new position in LeMaitre Vascular in the second quarter worth $47,000. Geneos Wealth Management Inc. grew its position in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares in the last quarter. Quarry LP lifted its holdings in LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 529 shares during the last quarter. Kestra Advisory Services LLC bought a new position in shares of LeMaitre Vascular during the fourth quarter valued at approximately $68,000. Finally, Kemnay Advisory Services Inc. bought a new position in LeMaitre Vascular during the 4th quarter worth $80,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

Analyst Ratings Changes

LMAT has been the subject of a number of research analyst reports. Barrington Research upped their target price on shares of LeMaitre Vascular from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Roth Mkm reaffirmed a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research note on Thursday, February 26th. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Citizens Jmp raised their price target on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.60.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.